Glint Pharmaceuticals

Glint Pharmaceuticals Receives FDA IND Acceptance for Clinical Study for Phase 1/2 Clinical Trial of Antibiotic Drug-Releasing Contact Lens, ACL5

UF startup Glint Pharmaceuticals (Glint), a clinical-stage biotechnology company focused on developing a next-generation contact lens drug delivery technology, announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate its antibiotic drug delivery contact lens, ACL5. Glint anticipates beginning the investigation in Q2 2023.